Literature DB >> 11495350

A direct chemical interaction between dynorphin and excitatory amino acids.

A Woods1, A Zangen.   

Abstract

The endogenous opioid peptide dynorphin A elicits non-opioid receptor-mediated neurotoxic effects. These effects are blocked by pretreatment with N-methyl-D-aspartate (NMDA) receptor antagonists. Herein, the mechanism for the non-opioid effects of dynorphin and related peptides was studied by matrix-assisted laser desorption ionization (MALDI) mass-spectrometry. We observed that both glutamate or aspartate bind non-covalently to dynorphin A and dynorphin 2-17. However, when dynorphin A or dynorphin 2-17 were added to an equimolar mixture of Glutamate and Aspartate, they both complexed preferentially with glutamate. These data may explain the non-opioid physiological effects of dynorphin A and related peptides and indicate that the direct chemical interaction between neurotransmitters should be monitored when studying interactions between different neurochemical systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495350     DOI: 10.1023/a:1010903215566

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  24 in total

Review 1.  Brain uptake of glutamate: food for thought.

Authors:  D Attwell
Journal:  J Nutr       Date:  2000-04       Impact factor: 4.798

Review 2.  Opioid and nonopioid cardiovascular effects of dynorphins.

Authors:  M Dumont; S Lemaire
Journal:  Adv Pharmacol       Date:  1997

3.  Differential sensitivity of recombinant N-methyl-D-aspartate receptor subunits to inhibition by dynorphin.

Authors:  U Brauneis; M Oz; R W Peoples; F F Weight; L Zhang
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

Review 4.  Non-opioid effects of dynorphins: possible role of the NMDA receptor.

Authors:  V K Shukla; S Lemaire
Journal:  Trends Pharmacol Sci       Date:  1994-11       Impact factor: 14.819

5.  Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats.

Authors:  B H Herman; F Leslie; A Goldstein
Journal:  Life Sci       Date:  1980-09-08       Impact factor: 5.037

6.  Nonopiate effects of dynorphin and des-Tyr-dynorphin.

Authors:  J M Walker; H C Moises; D H Coy; G Baldrighi; H Akil
Journal:  Science       Date:  1982-12-10       Impact factor: 47.728

7.  Dynorphin1-13: interaction with other opiate ligand bindings in vitro.

Authors:  J Garzón; P Sánchez-Blázquez; J Gerhart; H H Loh; N M Lee
Journal:  Brain Res       Date:  1984-06-08       Impact factor: 3.252

8.  Dynorphin potentiation of [3H]CGP-39653 binding to rat brain membranes.

Authors:  M Dumont; S Lemaire
Journal:  Eur J Pharmacol       Date:  1994-12-12       Impact factor: 4.432

9.  Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism.

Authors:  A I Faden
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

10.  Characterization of non-opioid [3H]dynorphin A-(1-13) binding sites in the rat heart.

Authors:  M Dumont; S Lemaire
Journal:  J Mol Cell Cardiol       Date:  1993-08       Impact factor: 5.000

View more
  5 in total

1.  Involvement of glutamate neurotransmission in the development of excessive wheel running in Lewis rats.

Authors:  M Schwendt; R Duncko; A Makatsori; F Moncek; B B Johansson; D Jezova
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 2.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

Review 3.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

4.  Mass Spectrometric Imaging of Ceramide Biomarkers Tracks Therapeutic Response in Traumatic Brain Injury.

Authors:  Damon C Barbacci; Aurelie Roux; Ludovic Muller; Shelley N Jackson; Jeremy Post; Kathrine Baldwin; Barry Hoffer; Carey D Balaban; J Albert Schultz; Shawn Gouty; Brian M Cox; Amina S Woods
Journal:  ACS Chem Neurosci       Date:  2017-08-14       Impact factor: 4.418

5.  A non-opioid pathway for dynorphin-caused spinal cord injury in rats.

Authors:  Yu Chen; Liangbi Xiang; Jun Liu; Dapeng Zhou; Hailong Yu; Qi Wang; Wenfeng Han; Mingming Guo
Journal:  Neural Regen Res       Date:  2012-04-15       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.